Clinical Research
ACEMg for GJB2 Connexin 26
Advancing research in pediatric hereditary hearing loss
Soundbites for GJB2 Connexin 26 is the scientifically validated biomedicine ACEMg, designed to slow the progression of hearing loss in children with GJB2 mutations using a precise formula of beta-carotene (a vitamin A precursor), vitamins C and E, and magnesium.
Mechanism of Action
Counteracts Oxidative Stress
ACEMg works to counteract oxidative stress in cochlear cells, which is a key driver of hearing loss progression in GJB2 mutations.
Preserves Gap Junction Function
Helps preserve gap junction function in the cochlea, which is critical for maintaining proper communication between cells and ion balance.
Maintains Cochlear Homeostasis
Supports the maintenance of cochlear homeostasis, helping to create an optimal environment for preserving hearing function.
Scientific Evidence
ACEMg as Soundbites offers a non-invasive, preventive option for children at risk of progressive hereditary hearing loss. Our approach is backed by peer-reviewed preclinical study data and clinical case reports.
The formulation is delivered in easy-to-administer twist-off softgels, designed specifically for pediatric use.
Featured Publication
“ACEMg supplementation ameliorates progressive Connexin 26 hearing loss in a child”
Peer-reviewed case report
Read the Case ReportResearch Background
Research into micronutrient-based hearing preservation begins at University of Michigan
Landmark preclinical study demonstrates 75% reduction in noise-induced hearing loss
NIH and European Commission funded translational research
Ongoing clinical research for pediatric hereditary hearing loss applications
About GJB2 / Connexin 26 Mutations
Mutations in the GJB2 gene, which encodes the Connexin 26 protein, are the most common cause of hereditary non-syndromic hearing loss. Connexin 26 forms gap junctions that are essential for potassium recycling in the cochlea.
Children with GJB2 mutations often experience progressive hearing loss that can significantly impact language development and quality of life. Early intervention and preventive approaches are critical for these patients.
ACEMg supplementation represents a novel approach to supporting cochlear health in children with GJB2 mutations by addressing oxidative stress and supporting gap junction function.
For Researchers and Clinicians
If you are a researcher or clinician interested in exploring ACEMg for pediatric hereditary hearing loss, we welcome your inquiry. Our team can provide detailed scientific information, research protocols, and formulation specifications.
Phone
877-439-7722Please include “Clinical Research Inquiry” in your subject line.
Soundbites for GJB2 Connexin 26 is currently only available for clinical research purposes. It is not available for direct consumer purchase. The information on this page is intended for healthcare professionals and researchers. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.